Insmed (NASDAQ:INSM) Director Sells $1,453,900.00 in Stock

Key Points

• Melvin Md Sharoky, a director at Insmed, sold 10,000 shares of the company's stock for approximately $1.45 million, resulting in a 3.67% decrease in his position.
• Insmed's stock fell by 1.9% on Monday, trading at $143.14, while the company reported a negative earnings per share of ($1.70) in its last quarterly earnings, missing analyst expectations.
• Equities research analysts have upgraded Insmed’s stock, with target prices ranging from $115.00 to $165.00, as the company is forecasted to have a consensus rating of "Moderate Buy".

Insmed, Inc. (NASDAQ:INSM - Get Free Report) Director Melvin Md Sharoky sold 10,000 shares of the company's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director owned 262,675 shares in the company, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Melvin Md Sharoky also recently made the following trade(s):

• On Wednesday, August 20th, Melvin Md Sharoky sold 10,000 shares of Insmed stock. The stock was sold at an average price of $129.50, for a total transaction of $1,295,000.00.

Insmed Stock Down 1.9%

Shares of NASDAQ INSM traded down $2.79 during trading on Monday, hitting $143.14. The stock had a trading volume of 1,977,691 shares, compared to its average volume of 2,765,134. The firm has a fifty day moving average of $119.40 and a two-hundred day moving average of $92.09. The company has a market capitalization of $30.26 billion, a PE ratio of -25.07 and a beta of 0.97. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $149.08.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. During the same period in the previous year, the business earned ($1.94) earnings per share. The firm's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Leerink Partners increased their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Jefferies Financial Group increased their target price on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Mizuho increased their target price on shares of Insmed from $130.00 to $165.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 13th. Stifel Nicolaus increased their price target on shares of Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Finally, Citigroup raised shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $139.86.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. M&T Bank Corp raised its stake in shares of Insmed by 4.7% in the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the last quarter. Snowden Capital Advisors LLC grew its holdings in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after acquiring an additional 158 shares during the period. First Horizon Advisors Inc. grew its holdings in Insmed by 24.8% during the second quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 186 shares during the period. ORG Partners LLC grew its holdings in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 196 shares during the period. Finally, Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.